Today, it is increasingly recognized that more and more unmet
medical needs may be met by tackling the undruggable targets in the
realm of drug discovery. Along with other novel approaches,
allostery has shown its potential to open another window for drug
developers to broaden and diversify the drug space. Allostery is an
inherent property of biomacromolecules in which topographically
distinct binding sites within a protein are functionally coupled.
Allosteric modulation of proteins enables exquisite control over a
number of biological processes, presenting itself as a unique
solution for drug developers to aim at undruggable targets.
Furthermore, recent allosteric drugs, both approved and those still
in clinical development stages, have simply demonstrated allostery
as a proven drug discovery approach.
Nowdays, NUTSHELL has been generating its own pipeline as well as enabling other academic and industry collaborators to develop allosteric drug. With our NUTSHELL proprietary platform and its early stage yet fast evolving allosteric based pipelines, NUTSHELL biotech is now becoming an oncology focused and novel target centered company and pioneering in allosteric drug discovery.
We believe that our people and culture are our greatest assets.
Innovation: We strive to be curious, inspired and think out of the box.
Teamwork: We hail from diverse backgrounds, different expertise, and deliver our promise to putting the team above self.
Humility: We aim to be open-minded and to learn from others.